中国调研在线网讯

【关键词】Spectrum Quarterly Deal Review—Fourth Quarter 2005

【报告格式】 印刷版/电子版 

【交付方式】 特快专递/E-MAIL

【释放日期】 2006年2月

【报告页数】 页

【报告字数】 字

【图表数量】 个

【报告价格】 印刷版：20000元          电子版：20000元              印刷＋电子：20100元

【其它信息】

【订购热线】 010-58613285                58613275                        网上订购    邮件订购

 

 

 

    In This Issue…Aside from biotechnology’s continued hot streak on Wall Street, the fourth quarter was a quiet one for the life sciences industry, which raised only $6.4 billion in financings, the lowest quarterly total of 2005. Only four initial public offerings (IPOs) were made in the United States, and both alliance and ownership activity dropped dramatically. Secondary public offerings (SPOs) were the only financial vehicle that increased over the third quarter’s totals, and biotech stocks turned in a strong fourth quarter, outperforming the life sciences industry and the U.S. economy as a whole. In this report, we review the fourth quarter’s IPOs, SPOs, debt financings, private placement and venture capital activity, ownership changes, and company alliances. We also examine the most active pharmaceutical and biotech companies of the quarter. In addition, we take an in-depth look at the year-end bidding war for Guidant that drew the attention of the life sciences industry—as well as the business world in general—by highlighting the current and likely continued profitability of drug-eluting stents in the cardiovascular industry.

 

 

Major Corporate Events in Cardiology—A Year-End Bidding War over Drug-Eluting Stents

A Brief Look at Guidant

Why Guidant Was Attractive to Johnson & Johnson

Why Guidant Was Attractive to Boston Scientific

Backed by Abbott, Boston Scientific Prevails

Warning Letter from the FDA and Device Safety Issues

Patent Struggles Continue

Future Acquisition Candidates for Johnson & Johnson

Financings

Initial Public Offerings

Secondary Public Offerings

Debt Financings

Private Placements and Venture Capital

Ownership Changes

Novartis/Chiron

Allergan/Inamed

Amgen/Abgenix

St. Jude Medical/Advanced Neuromodulation Systems

Alliances

AstraZeneca/AtheroGenics

Pfizer/Incyte

Roche/BioCryst Pharmaceuticals

Novartis/Astex Therapeutics

Most Active Pharmaceutical Companies

Most Active Biotechnology Companies

Figure 1 Drug-Eluting Stents Table 1 Launch Date for Drug-Eluting Stents

Figure 2 Worldwide Market Share of Drug-Eluting Stents, 2005

Table 2Major Milestones in the Bidding War for Guidant

Figure 3 Worldwide Sales Comparison: Boston Scientific’s Taxus Stent vs. Cordis/Johnson & Johnson’s Cypher Stent

Figure 4 Life Sciences Financings, First Quarter 2004 Through Fourth Quarter 2005

Figure 5 Life Sciences Financings by Transaction Type, Fourth Quarter 2005

Table 3 Biotechnology Component of Financing, Fourth Quarter 2005

Table 4 U.S. Life Sciences Initial Public Offerings, Fourth Quarter 2005

Table 5 Non-U.S. Life Sciences Initial Public Offerings, Fourth Quarter 2005

Figure 6 Life Sciences Secondary Public Offerings, First Quarter 2004 Through Fourth Quarter 2005

Table 6 Top Ten Life Sciences Secondary Public Offerings, Fourth Quarter 2005

Figure 7 Life Sciences Debt Financings, First Quarter 2004 Through Fourth Quarter 2005

Table 7 Top Ten Life Sciences Debt Financings, Fourth Quarter 2005

Figure 8 Life Sciences Private Placement Funding, First Quarter 2004 Through Fourth Quarter 2005

Table 8 Top Ten Life Sciences Private Placements, Fourth Quarter 2005

Figure 9 Life Sciences Venture Capital Funding, First Quarter 2004 Through Fourth Quarter 2005

Table 9 Top Ten Life Sciences Venture Capital Deals, Fourth Quarter 2005

Table 10 Top Ten Life Sciences Ownership Changes, Fourth Quarter 2005

Table 11 Top Ten Life Sciences Alliances, Fourth Quarter 2005

Figure 10 Alliance Participation by Company Type, Fourth Quarter 2005

Figure 11 Alliances by Transaction Type, Fourth Quarter